Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR

Hormone Research

Volumn 62, Issue 5, 2004, Pages 227-232

  Jenkins, P J ^a   Emery, M ^a   Howling, S J ^b   Evanson, J ^a   Besser, G M ^a   Monson, J P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

Acromegaly; Growth hormone; IGF I; Pituitary; Sandostatin LAR

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TUMOR VOLUME;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES;

EID: 9244236636     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081418     Document Type: Article

References (27)

1. Bates AS, Van't Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-299.
2. Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, et al: IGF-I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3218-3221.
3. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al: Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 2000;85:526-529.
4. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, et al: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996;45:407-413.
5. Jenkins PJ, Plowman PN: Radiotherapy for acromegaly; in Wass JAH (ed): Handbook of Acromegaly. Bristol, BioScientifica, 2001, pp65-76.
6. Jenkins PJ, Elliott EL, Carson MN, Bates PR: Use of a national database to explore the effects of pituitary irradiation on serum GH and IGF-I in acromegaly. J Endocrinol 1999;163(suppl):OC4.
7. Jenkins PJ: The use of long-acting somatostatin analogues in acromegaly. Growth Horm IGF Res 2000;10(suppl B):S111-S114.
8. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, et al: Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995;80:2768-2775.
9. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ: Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994;79:1416-1423.
10. Lancranjan I, Atkinson AB: Results of a European multicentre study with sandostatin LAR in acromegalic patients. Sandostatin LAR group. Pituitary 1999;1:105-114.
11. Ayuk J, Stewart SE, Stewart PM, Sheppard MC: Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87:4142-4146.
12. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-2786.
13. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al: Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-4563.
14. Morrell DJ, Dadi H, More J, Taylor AM, Dabestani A, Buchanan CR, et al: A monoclonal antibody to human insulin-like growth factor-I: Characterization, use in radioimmunoassay and effect on the biological activities of the growth factor. J Mol Endocrinol 1989;2:201-206.
15. Clayton RN, Stewart PM, Shalet SM, Wass JA: Pituitary surgery for acromegaly. Should be done by specialists. BMJ 1999;319:588-589.
16. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G: Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian multicenter octreotide study group. Eur J Endocrinol 1995;133:430-439.
17. Lundin P, Eden Engstrom B, Karlsson FA, Burman P: Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: Evaluation with serial MR. AJNR Am J Neuroradiol 1997;18:765-772.
18. Stevenaert A, Beckers A: Presurgical Octreotide: Treatment in acromegaly. Metabolism 1996;45(suppl 1):72-74.
19. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB: Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 2000;53:719-724.
20. Lucas T, Astorga R, Catala M: Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 2003;58:471-481.
21. Freda PU: Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87:3013-3018.
22. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al: Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002;56:65-71.
23. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, et al: Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of shortterm results? J Clin Endocrinol Metab 2003;88:3090-3098.
24. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, et al: Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040-1048.
25. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, et al: Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:5194-5200.
26. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC: Depot long-acting somatostatin analog (sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-3272.
27. Colao A, Ferone D, Cappabianca P, Del Basso De Caro ML, Marzullo P, Monticelli A, et al: Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308-3314.